A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
- PMID: 11371134
- DOI: 10.1006/gyno.2001.6182
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
Abstract
Objectives: To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients.
Methods: Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles.
Results: Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations.
Conclusions: CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
Copyright 2001 Academic Press.
Similar articles
-
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.Gynecol Oncol. 2000 Dec;79(3):463-5. doi: 10.1006/gyno.2000.5984. Gynecol Oncol. 2000. PMID: 11104620 Clinical Trial.
-
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2002 Jan;84(1):32-5. doi: 10.1006/gyno.2001.6441. Gynecol Oncol. 2002. PMID: 11748972 Clinical Trial.
-
A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2006 Mar;100(3):586-90. doi: 10.1016/j.ygyno.2005.09.032. Epub 2005 Oct 24. Gynecol Oncol. 2006. PMID: 16249022 Clinical Trial.
-
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Cancer Treat Rev. 2016. PMID: 26559739 Review.
-
[Ovarian cancer--therapeutic options after the failure of the first line of treatment].Ginekol Pol. 2004 Jan;75(1):58-64. Ginekol Pol. 2004. PMID: 15112475 Review. Polish.
Cited by
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17. Gynecol Oncol. 2011. PMID: 21414654 Free PMC article. Clinical Trial.
-
Ovarian cancer: emerging molecular-targeted therapies.Biologics. 2012;6:147-54. doi: 10.2147/BTT.S24155. Epub 2012 Jun 20. Biologics. 2012. PMID: 22807625 Free PMC article.
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical